Stock comparison

BMYvsVTRS

Bristol-Myers Squibb CovsViatris Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

VTRS

Viatris Inc

$14.75

+26.61%

Pharmaceuticals$15.6BNASDAQ

60-day price, rebased to 100

BMY +8.73% · VTRS +13.72%

Round-by-round

BMY 4·VTRS 2

EdgeVTRS

Valuation upside

+2.90% vs +97.70% to DCF fair value

EdgeBMY

Balance-sheet strength

Altman Z 2.20 vs 0.89

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 4.00 (of 9)

EdgeBMY

Growth + margins

Rule-of-40 26.40 vs 10.00

EdgeVTRS

60-day momentum

+8.73% vs +13.72% price return

EdgeBMY

Market-cap liquidity

$117.4B vs $15.6B

Verdict

Across6categories,BMYtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorVTRS

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.